PR Newswire·Sep 10, 2026, 9:00 AM ET

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NRSN

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.
Management will deliver a corporate presentation on Tuesday, September 15, 2026, at 4:30 p.m. ET regarding PrimeC, its lead drug candidate for amyotrophic lateral sclerosis (ALS).
The presentation will cover recent clinical progress, regulatory preparations for the Phase 3 PARAGON trial, and strategies to advance PrimeC toward approval in the U.S. and other key markets.
One-on-one investor meetings with institutional investors will be available during the conference via the H.C. Wainwright platform or through the company's investor relations team.
PrimeC is a novel extended-release oral fixed-dose combination of ciprofloxacin and celecoxib designed to target neuroinflammation, oxidative stress, iron accumulation, and RNA regulation.
The company recently published Phase 2b PARADIGM study results in JAMA Neurology, showing slowed functional decline relative to placebo and biomarker changes consistent with PrimeC's mechanism of action.
The U.S. Food and Drug Administration (FDA) has cleared the initiation of the pivotal Phase 3 PARAGON trial in ALS, with the company collaborating on an optimized study design.
NeuroSense is developing novel treatments for severe neurodegenerative diseases including ALS and Alzheimer's disease.
Forward-looking statements in the release include risks related to trial timing, financing, Nasdaq compliance, and potential delays in the Canadian New Drug Submission.